Executive readout · one minute
Webcast research workspace
Read the call alongside every captured source. Transcript, audio stay in one workspace.
Conference · 2026-11-17
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Executive readout · one minute
Read the call alongside every captured source. Transcript, audio stay in one workspace.
Research coverage
2 live sources
Switch sources without leaving this page or losing your listening position.
Open the source you need; every reader stays inside this workspace.
Hi, everyone. My name is Farzin Haak, one of the biotech analysts at Jefferies. It's my pleasure to introduce David Haak, CEO, and Philip Sabaj, CFO of Innovation Bio. Maybe, David, you can start off giving a quick one-minute intro to the company.
Yeah, so we have, I guess, to focus on three programs. So Ibtrozi is a commercial-stage asset, approved a year ago in the United States, also approved in China and Japan, and about to be approved in Europe. We've had about a year of sales, and we are already a market leader in our space. We are also a market leader in first-line patients. If you look at our quarter-on-quarter growth in the last quarter, it was up 18% in spite of a 20% drop in new patient alerts in testing for Rospin, so I would say we're about at 100 2 million for the year so far. And I think that if you look at our data, our 90% response rate and 50-month duration of response have not been matched by anyone in the first-line space. And the second-line indication are... 56% response rate and 66% intracranial response rate have not been matched by anyone in the second line indication. And even like our tolerability and safety, we are now the only brain penetrant RAS1 TKI that does not have a CNS warnings and precautions. So I would say that that program is going very well. Our second program, Safucitinib, is a mutant IDH1 glioma drug. We are in four studies right now. Unlike the only competitor in the space, Vorocitinib, which is approved only in the low-grade glioma indication, we have shown activity in both low-grade and high-grade glioma. If you look at Vorosutinib's most recent three-year data, In the low rate indication, their response rate was 21%. In the same indication, our response rate was 52%. If you look at their progression-free survival at three years, in the low rate indication, it was 52% PFS. Ours was 79%. So we think that this drug is extremely active in the low-grade indication. If you look at varacitinib's response in high-grade glioma, it was zero. Ours was 17%, with a third of those being complete responses. So again, we believe that safucitinib is extremely active in low-grade setting as well as the high-grade setting. We're in a number of trials. Our earliest data will read out in 2027. We're going to see grade 3 oligo patients, a form of high-grade glioma that will start to have data. And in the second half of next year, we're also enrolling patients in a post-voracitinib failure indication. That's clearly a really big indication, and we'll also have some data in that indication probably in the second half of next year. And then we have two other trials we're reading out with a PFS endpoint later on in 2029. But our first data on response rate we'll start to read out in the second half of next year. We believe that if you look at the precedent set by companies like Chimerics, where their drug was approved on 11 responses in 50 patients, We think, you know, a 20% or so response rate or higher is potentially sufficient to get approval in an indication where there is no other therapy. And, you know, given the activity that we've seen with Safflucetupin, both the low-grade and high-grade indications, we think that. We're very bullish on that program. Our third program is a drug-drug conjugate program. DDCs are like an ADC without the A, so no antibody. We're fusing two small molecules together. Because small molecules are so much smaller than antibodies, they can go places that antibodies can't go, and they can also do things that antibodies and antibody-drug conjugates can't do. I think a very exciting example of the DDC, actually the only company that we are aware of that has a program like ours is HALDA. As you know, HALDA's prostate drug, based on 10 patients, the data was acquired for $3 billion, and they just recently announced post-extending response rates of 69%. Their molecule is basically a DDC. We have an entire platform based around this DDC concept, and we're going to be making an announcement on that program in the next six weeks or so. A very brief announcement, and then we're going to follow that up with an R&D day earlier next year. So we think that's an extremely exciting platform technology that could yield many molecules to the pipeline.
Makes sense. I want to start with the sephucetinib because I think that's the clear value driver in the future. So if it works across the newly diagnosed recurrent high-grade post-fora, how should we think about the addressable patient population? Which one is the biggest driver for the commercial opportunity?
So if you look at the division of low-gradient high-grade glioma among brain tumors, it's about 50-50. But the difference is... So IDH1 mutations make patients actually live longer. So if you look at the progression pre-survival of IDH1 mutant brain tumors, it's actually extremely long compared to non-IDH1 driven. But IDH1 is also relentless, so they will always continue to grow. But they can, so low-grade patients can live 20-plus years. Even high-grade IDH1, almost like astrocytoma, even, you know, GBM, they can still live six-plus years, unlike regular GBM. So what's unique about IDH1 as a mutation is that it makes the tumor relentless, but it also makes the patient survive for long periods of time. So you do need to treat these tumors because, especially when they occur in younger patients, and they will grow relentlessly, they will compromise things like, you know, your neurostatus, your vision, your hearing, you know, all the things that you expect brain tumors to do. So it's very important that you address it. You can't give repeated surgeries to young patients. You can't just keep cutting out parts of the brain. You can't continually give radiotherapy, which is clearly very damaging to brain tissue. You can't give chemotherapy. No patient wants to take chemotherapy forever. So you do need an oral therapy. We think our once-a-day pill is a very attractive option, and we can show that we continue to have the results that we've shown so far. So the reason the market opportunity is so large is because when you have 20 years of, you know, patients taking the drug, you're talking about a revenue-stacking opportunity you just don't see in general in oncology. So that's in the low-grade setting. In the high-grade setting, even though it's shorter than low-grade, we're still talking about, you know, up to six-plus years in the high-grade setting. So that's still an attractive option. So even though the roughly 50-50 spin of high-grade to low-grade is... It's how the indications break out. The longer duration of therapy likely and low-grade indications makes that a more compelling... A more compelling commercial opportunity. Now, when I mentioned earlier that voracitinib has a 21% response rate in low grade, we have a 52% response rate in low grade. So when people ask us, why do we believe this drug will work after voracitinib? Well, we have 31 percentage points more response rate in the same indication. So we do believe SAC will work after voracitinib. We believe that if it works after voracitinib, people will use it after voracitinib and even instead of voracitinib. So, we actually believe that's the path to get, you know, the entire Gliela market.
Maybe to rephrase that, like mechanistically, why, how SAFO works differently from Borat to give that differential responses?
You know, we've made the point before that even though they both hit IDH1, we are seeing activities with sapocinib that you don't see with boracitinib. So boracitinib's main adverse event is liver function test abnormalities. We don't generally see that. If you look at our adverse events, even though almost all of them are grade one, we do see out of our top seven adverse events, five of them are immune-related. So we see things like alopecia, rash, arthralgia, like rheumatoid arthritis, pruritus. And we believe that if we look at our responses, they take six to 12 months to kick in, sometimes even longer. In fact, even between years two and year three, we had an additional 8% response rate, going from 44% to 52% in our recent publication. So when you see those really long times to responses and then really durable responses, so we have a GBM that's been in the CR for three and a half years. We have another high-grade oligodendroglioma that's been gone for two years. When you see those really long onset to response and then very durable responses, it's very reminiscent of immuno-oncology agents. So we actually believe that sapocytinib has a significant immune component to its activity, and we believe that that differentiates it from boron and why we believe we will see responses after boron failure. And also, we're already seeing responses and indications that boron's response rate is zero.
Got it. Any color on the enrollment across SIGMA, the oligodendric glioma study, and the post-vora study?
So, you know, we haven't given any guidance to the street, but I would say that all the studies have been enrolling very well. We've committed publicly that we will have a minimum of 20 grade 3 oligopatients enrolled by this year, and we are absolutely on track for that. If you look at the post-Vora failure study, which is, you know, one of the earlier studies to read out, the reason that's so attractive is that Cervia has now treated, you know, thousands of patients with Vora. If you look at the progression rate on voracitinib, 23% of patients in the indigo study progressed at one year. So there are thousands of patients who have already failed Vora and will continue to fail. So we believe we need to enroll 50 of those patients and show 10 responses to be in a position to take that to the FDA for a potential consideration of approval. So I think that, you know, there are a lot of patients who are failing vorocytinib. That study should enroll very quickly. We're already on track to get the grade 3 oligos that we've already committed publicly. We'll probably exceed that target. And so I think that's a testament to how many of these patients there are and the size of the commercial opportunity.
Is there a combination of the patient number, confirmed responses, and follow-up for the 20% benchmark that you mentioned? Like, have the conversations with the FDA for a path?
Yeah, you know, if you look at chimerics, I think, you know, they had 50 patients in their pivotal study. They had 11 responses, 22% response rate, and they were approved. So I think that we've said, you know, what the FDA wants to see is that your confidence interval between your response rate It doesn't overlap with the response rate of the other available therapies, which in this case would be chemotherapy with a mid-single-digit response rate. So we do think that somewhere in the ballpark of 20% response is enough to have non-overlapping conference intervals to get approval. And then duration of response needs to be something that FDA considers meaningful. We haven't really talked publicly about what that number is, but I think a lot of people figure that's just a number of months. These are patients who are young, they're progressing relentlessly, they're going to do badly if they're not treated, so I think that's a very, very unmet need, and the data that we've shown, you know, 52% response rate, low grade, with 79% PFS at three years, I mean, that certainly would beat the bar, I would think.
For the standard of care, is it like more six months for the duration of response?
You know, I think that people use that number often, but, you know, again, we haven't released.
And then for the post-Vora, you mentioned that it could enroll faster, but you're guiding to both data sets most likely in second half 27.
Yeah, we haven't given any guidance on that. I do think that there are thousands of patients at this point who have failed Vora. As I said, we need 50 of them, and we need to see about 20% responses, so hopefully around 10 patients or more. And I think that would do the trick. So we do think that trial will enroll pretty quickly, and we think that we're already getting lots of inbounds. For patients who want to be on staff, we just give them the data we've presented publicly so far. So I do think that there's a lot of interest in that trial and it will enroll well.
Got it. One of the things is that you just mentioned that there's a delayed response sometimes. How could that complicate FDS interpretation of the efficacy? Could that be?
Well, I think whatever response rate we do report, it's only going to get better from there. So, you know, the responses can kick in. I think our earliest response we've ever seen is around two weeks, but most of the responses kick in at six to 12 months. As I mentioned, between years two and year three, we had 8% more responses in our Daiichi study. So these patients can continue to improve for years after their initial responses. So, you know, we do think that we'll take the data that we have next year and start to talk to FDA about that. But we would anticipate whatever number we put out, that will probably improve over the subsequent years.
Is there a benchmark similar to 20% for post-fora?
I think that 20%, you know, we know that chimerics was approved on a 22% response rate, so I think that's, you know, if we had to give a precedent, that would be a reasonable one.
Just to reiterate on what David was doing, the 20% is because of 50 patients, if you want, and that's 10, the 11th of chimerics, but what the FDA wants to see is just separation. So if your response rate is higher, theoretically, they need to see less patients because you just want to see statistical separation from the single-digit response rate of chemo. And that's true for both scenarios, the post-Vora and Nigo, just like the great-feely-good and oglioma, because in both cases, there is nothing else but salvage chemo.
Makes sense. Okay, so switching gears to Iptrosi. That market is considered, the ROS1 market is considered niche by many, but how do you see the long-term opportunity unfolding as you have launched into that?
So the market is niche in terms of how many new patients are diagnosed a year. It's about 3,000 patients. If you multiply that times the drug price, it's still about a billion dollars a year in the theoretical maximum potential of that opportunity. What's unique about ROS1 is that... With diptrozzi, our duration of response is 4.2 years. That means that every patient in year one, let's say we have 3,000 patients who get drugged, and that's about a billion. That means everyone in year one will likely go to year two, where you'll have another 3,000 new patients, so that will stack to 2 billion. By the year three, you'll have 3 billion. By year four, you'll have 4 billion. And so even for a 3,000-patient incidence indication, it's still potentially a pretty large commercial indication because of the revenue stacking. You don't see generally 4.2 years of DOR for most drugs. Most people are pretty happy if your duration of response is in the 6- to 12-month range. So I think that having such a long DOR and a 90% response rate, which has not been matched by many drugs in any oncology indication with any drug, I think makes this a very uniquely attractive commercial opportunity.
And in third quarter, you had a softness with the new patient starts and also with the NGS testing. So is there something, a temporary softness, or is more of a structural change in how the disease is being diagnosed and treated?
You know, so we buy new patient alerts for new Rosslyn diagnoses from all the testing labs. And in the last quarter, there was a 20% drop in new alerts. But in rare indications, that just happens. It just happens. We know that there was also a 14% drop in KRAS in this last quarter. In the previous quarter, there was a 19% drop in ALP diagnoses. When you have rare mutations, you know, 10 patients here or there can really change the testing rate, the diagnosis rate. So we don't think that it's any trend. We just think it's lumpiness. The most important thing is that in spite of a 20% drop in new patient diagnoses in that quarter, we still grew sales 18% in spite of that. Of course, it would have been higher than that had it been 20% more diagnoses, but we still grew over the previous quarter 18%, and we're still market leader, and we're also first-line share leader. So I think we're doing well. Clearly, I think that will equilibrate over time, so we don't expect that that's indicative of any change in how this drug is working or how the disease is being diagnosed.
And the community testing remains one of the key upside levers, and now that you're six quarters into the launch, have you seen any measurable increase in the NGS testing with the DNA RNA?
So we've made a concerted effort to actually look at centers where testing rates are on the low side, and with our efforts, we've actually been able to, at least in one center, double its testing rate and another one triple it. So we actually have made some strides in changing testing rates in large community centers. Academic centers, their testing rate is close to 100%, so there's not much room for improvement there. But in the community setting, there is room for improvement, and especially now in some of these large aggregators where they control many patients in many states, if you can change testing rates there, that clearly will have great ramifications for the product. So we are making a significant effort to educate centers on that, and we have had success in the centers that we've approached.
One of the common questions I get is, of course, the GSK market entry, and there seems to be a disconnect, but Iptros is the only one that doesn't have the CNS warning on the label, but do you think that doctors, investors, there's a disconnect, but do you think doctors understand the nuance between the two drugs, their profiles?
You know, I think that they need to read the labels. If you look at the, so the GSK drug is approved in the second line setting. If you look at the second line response rate of that drug, you know, it's 49%. Ours is 56%. So that's the label. If you look at the intracranial response rate for that drug, it's 48% or 66%. So just apples to apples in the second line indication, not really that close. And the other thing is that if you look at the safety side, not only is there a CNS warnings and precautions with that, but that's with only 14% of patients having one-year follow-up. We have four times that level of follow-up, so adverse events only accumulate with more time. So we expect those adverse events to grow further, and if you look at where we are right now with no CNS warnings and precautions, I think I mentioned previously that out of our top six adverse events, out of 337 patients, we only had one discontinuation. So we think that Petrosi's efficacy is not only by far the best with a 90% response rate and a 50-month duration of response, but our safety and tolerability also have not been matched. So we think we're in a good position.
So one of the other things is that it's a second-line label, so they're going to expand to the front-line label. We don't know when. We'll have maybe second F27. And is there any reason to believe that the label will change? If anything, it should get worse.
You know, I think the AEs will get worse, for sure. And the thing is that, even by next year, there won't be the length of follow-up that we have. So no one's going to have a 15-month follow-up, much less duration of response. Our duration of response is 15 months. I think it's going to be hard to beat. Our response rate is 90%. That's going to be hard to beat. So I just think that, you know, it's going to be difficult to overtake your trophy.
And you also have the adjuvant study, which they don't, they're not running. And what makes you believe that? The investors should, not investors, investigators should be interested to enroll the study, and how's that enrollment going?
So you make an interesting point that we are, we're actually the only ROS1 TKI being developed in the adjuvant setting. In order to be given that early in treatment of a patient, you have to be incredibly well-tolerated, and because we are incredibly well-tolerated, that study's enrolling beautifully, and we are going to be the only ROS1 TKI with an adjuvant label, we believe. So, that said, you know, I think that that increases the market even further. I think we've estimated about 30% larger commercial opportunity by moving into the adjuvant setting. And we also, when we look at the RET study with supracatinib, the hazard ratio of 0.17 in the Libretto 432 study is really extraordinary, and it gives us even more confidence that this study will not only be positive, but will actually read out sooner than we actually previously anticipated. So we believe that the RET study, the Libretto 432 study, is an example of what a great drug does in the adjuvant setting, and we believe that will reflect exactly the same way in the Iptrosy adjuvant study.
Makes sense. So a year from now, hopefully we'll all be back. What would need to be true for you to say that Iptrosy has meaningfully exceeded your expectations?
You know, I think if we just see the revenue stacking and the new patient share that we've talked about, I think it's all a first line game. So whoever wins first line wins the entire thing. So, you know, with our duration of response, we would expect to see that revenue stacking that we're talking about. I think that would make us feel that we've done a good job in executing it. And given the fact that in 12 months we've gone from nothing to majority market share and first line leader, I think our commercial team has done a great job. And I think we'll continue to execute.
Okay, and then on the BD front, so you guys have a strong balance sheet, and then you have successfully integrated the UnHard Acquisition. So what is the current appetite and capacity for in-licensing or even like M&A?
Well, like you said, Farzin, we have $660 million of cash in the last quarter, which puts us in a very comfortable position. We had enough cash to get to profitability prior to our rates, our convert rates back in June, so that gives us even more firepower. We are going to be very selective, but we are always actively looking. We think it's healthy for any biotech to confront itself to the rest of the market and to see what's out there and how good it can be, And how good it can be as an add-on to your company as well. So we're looking at things. We also have a base of operation in China, which is helpful to look at certain opportunities as well. So we'll see. We've not done anything yet because we didn't find anything which was good for us at the appropriate price. But who knows? We might.
And I think, you know, this brutal market conditions in the last few months, I think given the fact that we have so much cash on our balance sheet, it will further differentiate us from our peer group But I think they allow us to look at even more opportunities on the beauty front. So I think that's a potentially a really interesting.
I want to touch on the DDC update that you're going to have by year-end. So any high-level attributes of the platform like target selection, payloads, and teamwork focus that you can give us?
So we're not going to give that level of detail this year, but we intend to give that level of detail in our R&D day in the beginning part of next year.
Okay, so this year will be more of a...
Just to tell you where we are and what we're doing with the program, because there's been no update for a long time now. So we're going to tell you what we're going to do and where the program is, but next year we want to talk in more detail about exactly what we're doing and why and how.
So the HALDA one that you explained was an interesting one, because that led to a lot of stocks being moving because of the data, even in prostrate and other ones. But how do you envision in the longer run? Like, would it be more of a BD, or would you develop it in-house?
So, I mean, all of our GDCs have been made in-house. Completely like that. So this was the platform that, actually, was the basis upon which I found Innovation Bio in 2018. So we've been thinking about this for a long time. There are many, many things to consider in doing it. The chemistry is quite difficult, but the Haldig molecule is a very good example of how they've coupled an AR molecule to a BET inhibitor, and that molecule has really quite remarkable activity and, as I said, led to a $3 billion acquisition for 10 patients' worth of data. So we think that's a testament to how promising this platform is. We have many, many programs in our DDC platform, and we're going to announce a little bit of the beginning part of that and talk about what we're doing, but we are very excited about the program. We're going to clearly try to go where people haven't gone yet because we don't want to be following another program. So we have a pretty exciting platform that we think we're going to start talking about in detail in the first half of next year.
We're almost out of time maybe to wrap up. We know the cash, but what are the key catalysts that investors should be focused on over the next 6 to 12 months?
I think we should look at continuing at Trozi sales. I think we should do well there. Look at SAFU updates, you know, see what the response rate data are in 2027, the DDC update, especially with the R&D data, you'll get more of an understanding of what we're actually doing and why it's so promising, and then look for, you know, any other, if there's any BD or other opportunities that we decide to bring in-house.
So, all is great chatting with you guys. Thank you so much for your time. Thanks so much. Thanks, Pauline.
0:03 to 26:30 · One card per analyst, follow-ups included. Each plays from its start, and the one being answered is marked.
Hi, everyone. My name is Farzin Haak, one of the biotech analysts at Jefferies. It's my pleasure to introduce David Haak, CEO, and Philip Sabaj, CFO of Innovation Bio. Maybe, David, you can start off giving a quick one-minute intro to the company.
David Hung: Yeah, so we have, I guess, to focus on three programs. So Ibtrozi is a commercial-stage asset, approved a year ago in the United States, also approved in China and Japan, and about to be approved in Europe. We've had about a year of sales, and we are already a…
Also speaking: Philippe Sauvage